Silicon Laboratories financials
$221.17+0.06%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Jan 3 | FY24 Dec 28 | FY23 Dec 30 | FY22 Dec 31 | FY21 Jan 1 | FY20 Jan 2 | FY19 Dec 28 | FY18 Dec 29 | FY17 Dec 30 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $784.8M | $584.4M | $782.3M | $1.02B | $720.9M | $510.9M | $473.8M | $868.3M | $768.9M | $697.6M |
| Gross profit | $457.0M | $312.2M | $460.6M | $642.6M | $425.4M | $294.8M | $280.2M | $521.4M | $454.2M | $421.5M |
| Gross margin | 58.2% | 53.4% | 58.9% | 62.7% | 59.0% | 57.7% | 59.1% | 60.1% | 59.1% | 60.4% |
| Operating income | -$70.5M | -$165.5M | -$24.2M | $119.3M | -$32.8M | -$107.1M | -$88.6M | $85.2M | $85.0M | $66.3M |
| Net income | -$64.9M | -$191.0M | -$34.5M | $91.4M | $2.12B | $12.5M | $19.3M | $83.6M | $47.1M | $61.5M |
| Net margin | −8.3% | −32.7% | −4.4% | 8.9% | 293.7% | 2.5% | 4.1% | 9.6% | 6.1% | 8.8% |
| Diluted EPS | $-1.98 | $-5.93 | $-1.09 | $2.54 | $47.78 | $0.28 | $0.43 | $1.90 | $1.09 | $1.45 |
| EBITDA | -$32.5M | -$116.9M | $26.9M | $175.9M | -$14.8M | -$48.3M | -$35.7M | $145.2M | $127.0M | $107.2M |
| Operating cash flow | $95.7M | -$13.9M | -$30.3M | $71.8M | -$100.4M | $135.7M | $166.5M | $173.5M | $189.5M | $128.9M |
| Free cash flow | $61.8M | -$25.7M | -$53.1M | $45.3M | -$130.2M | $116.4M | $143.3M | $138.0M | $172.3M | $109.2M |
| Diluted shares | 32.7M | 32.2M | 31.8M | 36.0M | 44.3M | 44.4M | 44.3M | 44.0M | 43.3M | 42.4M |
Balance sheet
| Period end | Jan 3 | Dec 28 | Dec 30 | Dec 31 | Jan 1 | Jan 2 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $364.2M | $281.6M | $227.5M | $499.9M | $1.07B | $202.7M |
| Short-term investments | $79.4M | $100.6M | $211.7M | $692.0M | $964.6M | $522.0M |
| Total debt | $0.00 | $0.00 | $45.0M | $529.6M | $450.6M | $563.4M |
| Total assets | $1.27B | $1.22B | $1.44B | $2.17B | $2.96B | $1.99B |
| Total liabilities | $174.9M | $142.7M | $234.4M | $764.4M | $745.9M | $793.6M |
| Shareholders' equity | $1.09B | $1.08B | $1.21B | $1.41B | $2.21B | $1.20B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology